|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 September 2006, Vol. 108, No. 6, pp. 1787-1788.
34 + 43 = early human blood lineageALBERT EINSTEIN COLLEGE OF MEDICINE
In this issue of Blood, Vodyanik and colleagues show that the CD43 antigen can be used to separate hematopoietic progenitors cells derived from human embryonic stem cells from other CD34+ expressing cells.
Another promising avenue of research is the large-scale production of red blood cells (RBCs) for transfusion by differentiation of hESCs. While the current collection-based RBC supply is very safe, it remains vulnerable to emerging pathogens. Industrial production of RBCs from hESCs would eliminate the problem and yield cells of greater homogeneity. Importantly, since RBCs do not express human leukocyte antigens (HLAs) and are enucleated, two of the biggest issues in the hESC field, immune rejection and the possibility of oncogenic transformation, are greatly diminished. Recent work from the Douay lab in Paris has demonstrated that large numbers of apparently perfectly functional enucleated RBCs can be produced in culture by in vitro differentiation of human cord or peripheral hematopoietic stem cells,4 but RBCs produced from hESCs are probably not suitable for transfusion because they are similar to RBCs produced in the yolk sac and fetal liver early during human embryogenesis and express mostly embryonic and fetal globins.5 To solve these problems and create cells that are clinically useful, it is of the utmost importance to devise ways to purify hESC-derived hematopoietic stem cells in order to study them and compare them with their in vivo counterparts. In this issue of Blood, Vodyanik and colleagues demonstrate that leukosialin (CD43), a protein that is expressed on almost all hematopoietic cells, can be used as a marker to isolate all of the hematopoietic progenitors that are produced by differentiation of hESCs on OP-9, a mouse bone marrow stroma cell line. Previous reports on prospective identification of hESC-derived stem and progenitor hematopoietic cells by flow cytometry were based mostly on the use of the CD34 and CD45 markers. But CD45 is not expressed on the earliest hematopoietic cells, and CD34 is expressed in many lineages, including endothelial and mesenchymal, and therefore lacks specificity to separate the hematopoietic cells from the complex cell mixture that is produced by the coculture of hESCs and OP-9.
Vodyanik and colleagues have now shown that hESC-derived CD34+CD43+ cells are hematopoietic, while CD34+CD43–CD31+ KDR+ cells are endothelial and CD34+CD43– CD31–KDR– cells are mesenchymal. The authors were also able to distinguish 2 distinct waves of hematopoiesis: after 4 days of coculture, a first wave of CD34+CD43+ glycophorin A+ primitive erythromegakaryocytic progenitors develops. Starting on day 6 of coculture, this first wave is followed by the development of CD34+ CD43+ glycophorin A– multipotent lymphohematopoietic progenitors that can give rise in vitro to most myeloid lineages and to B and natural killer (NK) lymphocytes. Whether the hematopoietic cells produced from hESCs can also give rise to T cells, and whether they can be used for long-term reconstitution of lethally irradiated mice, remains to be determined. References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||
| |||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||
